Cheol Son, M. Kasahara, Tomohiro Tanaka, N. Satoh‐Asahara, T. Kusakabe, K. Nishimura, Y. Miyamoto, S. Kasama, K. Hosoda
{"title":"比较卡格列净与特内里格列汀对2型糖尿病患者基本代谢风险的研究原理、设计和方法(CANTABLE研究):随机、平行组比较试验方案","authors":"Cheol Son, M. Kasahara, Tomohiro Tanaka, N. Satoh‐Asahara, T. Kusakabe, K. Nishimura, Y. Miyamoto, S. Kasama, K. Hosoda","doi":"10.1007/s13300-019-00717-9","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":48675,"journal":{"name":"Diabetes Therapy","volume":"11 1","pages":"347 - 358"},"PeriodicalIF":2.8000,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s13300-019-00717-9","citationCount":"2","resultStr":"{\"title\":\"Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial\",\"authors\":\"Cheol Son, M. Kasahara, Tomohiro Tanaka, N. Satoh‐Asahara, T. Kusakabe, K. Nishimura, Y. Miyamoto, S. Kasama, K. Hosoda\",\"doi\":\"10.1007/s13300-019-00717-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":48675,\"journal\":{\"name\":\"Diabetes Therapy\",\"volume\":\"11 1\",\"pages\":\"347 - 358\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2019-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s13300-019-00717-9\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13300-019-00717-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-019-00717-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial
期刊介绍:
Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.